The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens
Open accessAbstract
BACKGROUND: Plasmodium vivax malaria is a major cause of morbidity and recognised as an important contributor to mortality in some endemic areas. The current recommended treatment regimen for the radical cure of P. vivax includes a schizontocidal antimalarial, usually chloroquine, combined with a 14 day regimen of primaquine. The long treatment course frequently results in poor adherence and effectiveness. Shorter courses of higher daily doses of primaquine have the potential to improve adherence and thus effectiveness without compromising safety. The proposed multicentre randomised clinical trial aims to provide evidence across a variety of endemic settings on the safety and efficacy of high dose short course primaquine in glucose-6-phosphate-dehydrogenase (G6PD) normal patients. DESIGN: This study is designed as a placebo controlled, double blinded, randomized trial in four countries: Indonesia, Vietnam, Afghanistan and Ethiopia. G6PD normal patients diagnosed with vivax malaria are randomized to receive either 7 or 14 days high dose primaquine or placebo. G6PD deficient (G6PDd) patients are allocated to weekly primaquine doses for 8weeks. All treatment is directly observed and recurrent episodes are treated with the same treatment than allocated at the enrolment episode. Patients are followed daily until completion of treatment, weekly until 8 weeks and then monthly until 1 year after initiation of the treatment. The primary endpoint is the incidence rate (per person year) of symptomatic recurrent P. vivax parasitaemia over 12 months of follow-up, for all individuals, controlling for site, comparing the 7 versus 14-day primaquine treatment arms. Secondary endpoints are other efficacy measures such as incidence risk at different time points. Further endpoints are risks of haemolysis and severe adverse events. DISCUSSION: This study has been approved by relevant institutional ethics committees in the UK and Australia, and all participating countries. Results will be disseminated to inform P. vivax malaria treatment policy through peer-reviewed publications and academic presentations. Findings will contribute to a better understanding of the risks and benefits of primaquine which is crucial in persuading policy makers as well as clinicians of the importance of radical cure of vivax malaria, contributing to decreased transmission and a reduce parasite reservoir. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01814683 . Registered March 18, 2013.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nkhoma, E. T., Poole, C., Vannappagari, V., Hall, S. A., & Beutler, E. (2009) · Blood Cells, Molecules, and Diseases · doi:10.1016/j.bcmd.2008.12.005 · Cited by 711
Determinants of relapse periodicity in Plasmodium vivax malaria
White, N. J. (2011) · Malaria Journal · doi:10.1186/1475-2875-10-297 · Cited by 679
Primaquine Therapy for Malaria
Baird, J. K., & Hoffman, S. L. (2004) · Clinical Infectious Diseases · doi:10.1086/424663 · Cited by 435
Alving, A. S., JOHNSON, C. F., Tarlov, A. R., Brewer, G. J., Kellermeyer, R. W., & Carson, P. E. (1960) · Europe PMC (PubMed Central) · Cited by 144
High-dose Primaquine Regimens against Relapse of Plasmodium vivax Malaria
Krudsood, S., Tangpukdee, N., Wilairatana, P., Phophak, N., Baird, J. K., Brittenham, G. M., & Looareesuwan, S. (2008) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2008.78.736 · Cited by 94
Consideration of ethics in primaquine therapy against malaria transmission
Baird, J. K., & Surjadjaja, C. (2010) · Trends in Parasitology · doi:10.1016/j.pt.2010.08.005 · Cited by 71
Pa, R., Toaliu, H., Kaneko, A., et al. (1992) · PubMed · Cited by 33
Cited by
Lam, M. M. C., Wyres, K. L., Duchêne, S., Wick, R. R., Judd, L. M., Gan, Y.-H., Hoh, C.-H., Archuleta, S., Molton, J. S., Kalimuddin, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05114-7 · Cited by 348
Alhumaid, S., Al Mutair, A., Al Alawi, Z., Alsuliman, M., Ahmed, G. Y., Rabaan, A. A., Al-Tawfiq, J. A., & Al-Omari, A. (2021) · Antimicrobial Resistance & Infection Control · doi:10.1186/s13756-021-00957-0 · Cited by 314
Viral Infections, the Microbiome, and Probiotics
Harper, A., Vijayakumar, V., Ouwehand, A. C., ter Haar, J., Obis, D., Espadaler, J., Binda, S., Desiraju, S., & Day, R. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.596166 · Cited by 177
Mahmoud, D. E., Faraag, A. H. I., & Abu El-Wafa, W. M. (2021) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-021-03158-4 · Cited by 26
Metadata
- Authors
- The IMPROV Study Group
- Venue
- BMC Infectious Diseases
- Published
- 2015-12
- Volume
- 15
- Issue
- 1
- Pages
- 558-558
- ISSN
- 1471-2334 (ISSN-L)
- OpenAlex
- W2227288692
- Cited by
- 277
- References
- 7
- FWCI
- 37.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. https://app.cochat.ai/papers/10.1186/s12879-015-1276-2
- The paper
- The IMPROV Study Group. (2015). Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens. BMC Infectious Diseases. https://doi.org/10.1186/s12879-015-1276-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.